TG Therapeutics signs manufacturing supply agreement with FUJIFILM Diosynth Biotechnologies
by
Contributor since / Followers
Contributor since / Followers
2 months ago
- TG Therapeutics (NASDAQ:TGTX) has signed a multi-year manufacturing supply agreement with FUJIFILM Diosynth Biotechnologies (OTCPK:FUJIY) for its multiple sclerosis drug.
- Under the deal, FUJIFILM Diosynth will provide secondary US-based manufacturing supply for Briumvi, TG Therapeutics’ FDA-approved drug for relapsing form of multiple sclerosis, at the company’s new biopharmaceutical manufacturing facility in North Carolina. The facility will be fully operational in 2025.
- Shares of FUJIFILM Diosynth were up roughly 4%, while TG Therapeutics (NASDAQ:TGTX) lost 10% on Monday following quarterly results.
- Source: Press Release